We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Management and Prognosis of Patients with Recurrent or Persistent/Progressive Uterine Carcinosarcoma.
- Authors
Tung, Hsiu-Jung; Chiang, Chi-Yuan; Chang, Wei-Yang; Wu, Ren-Chin; Huang, Huei-Jean; Yang, Lan-Yan; Lin, Chiao-Yun; Wang, Chun-Chieh; Chao, Angel; Lai, Chyong-Huey
- Abstract
Uterine carcinosarcoma (UCS) is a highly aggressive gynecologic malignancy. Recurrent or persistent/progressive disease is usually fatal. We aimed to investigate the management and prognosis of these patients. Clinical records of UCS patients from June 1987 to April 2020 were retrospectively reviewed. The stage was re-assigned with the FIGO 2009 staging system. Univariate and multivariate analyses were used to identify the independent predictors of survival after recurrence (SAR) and cancer-specific survival (CSS). Of the 168 patients, 98 experienced treatment failure. The median time to treatment failure (TTF) was 8.1 months (range: 0.0–89.1). The median follow-up time of censored patients was 32.0 months (range: 16.8–170.7). The 5-year SAR rates of those with recurrent or persistent/progressive disease were 7.6%. On multivariate analysis, salvage therapy mainly using radiotherapy (HR 0.27, 95% CI: 0.10–0.71) or chemotherapy (HR 0.41, 95% CI: 0.24–0.72) or chemoradiotherapy (CRT) (HR 0.33, 95% CI: 0.15–0.75) were associated with improved SAR, whereas disseminated recurrence was associated with significantly worse SAR (HR 3.94, 95% CI: 1.67–9.31, p = 0.002). Salvage therapy using radiotherapy or chemotherapy or CRT significantly improved SAR. Surgery significantly improved CSS but not SAR, adjusting for confounding factors.
- Subjects
CARCINOSARCOMAS; ENDOMETRIAL cancer; SURVIVAL; CANCER relapse; PROGNOSIS
- Publication
Current Oncology, 2022, Vol 29, Issue 10, p7607
- ISSN
1198-0052
- Publication type
Article
- DOI
10.3390/curroncol29100601